Where Tech Meets Bio
Subscribe
Sign in
Home
Weekly Highlights
Deep Dives
Sponsored Features
About
Latest
Top
Discussions
Weekly Tech+Bio Highlights #69: Big Pharma Keeps Tapping Multimodal AI Stacks
JPM takeaways; reality check on de novo antibody design; 2026 biotech & clinical AI reports, and more
5 hrs ago
•
Roman Kasianov
and
BiopharmaTrend
5
1
2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic
Forward signals for 2026—from >$1.3B in tracked financings led by Neuralink’s $650M round to a shoebox-sized biocomputer, driven device control, speech…
Jan 15
•
BiopharmaTrend
19
4
6
Weekly Tech+Bio Highlights #68: 2026 Opens Hot With M&As, Mega-Rounds, and Model Deployments
A first read on deal flow, platform launches, and strategic intent emerging as JPM week sets the tone for early 2026
Jan 13
•
BiopharmaTrend
and
Roman Kasianov
15
2
4
December 2025
Weekly Tech+Bio Highlights #67: Wrapping Up 2025
First-wave AI drug builder steps back from the clinic, platform-native developer heads for IPO, a model-discovered drug enters Phase 1, & pharma…
Dec 24, 2025
•
Roman Kasianov
and
BiopharmaTrend
14
5
Weekly Tech+Bio Highlights #66: AI Antibody Startup Hits Unicorn Status
Merck & Nvidia Debut Open-Source Drug Model; Microsoft’s Spatial Proteomics, & First Non-Profit Gets FDA Approval for Gene Therapy
Dec 15, 2025
•
Roman Kasianov
and
BiopharmaTrend
10
2
1
Aging, AI, and the Uneven Road to Longevity Medicine
Echoing notes from ARDD2025, we briefly overview geroscience, its fusion with AI, what companies pursue in this field and limitations on the way of…
Dec 11, 2025
•
BiopharmaTrend
16
1
Weekly Tech+Bio Highlights #65: Can AI Infrastructure Become Biotech’s Next Big Business?
2025 Pharma Review, Lilly Exec Explains Rationale Behind TuneLab AI Model Sharing & Biweekly News Roundup
Dec 9, 2025
•
Roman Kasianov
and
BiopharmaTrend
8
2
1
November 2025
Generative Diffusion in Molecular Design
A quick field guide to diffusion-based generators in molecular design—how they work, where they complement transformers, and who is deploying them today
Nov 27, 2025
•
BiopharmaTrend
18
1
Weekly Tech+Bio Highlights #64: Eli Lilly Reaches $1 Trillion Valuation
Merck's $3B AI drug discovery deal, new open-source virtual cell initiative, AI designing full-length antibodies, Europe’s first agentic AI…
Nov 25, 2025
•
BiopharmaTrend
and
Roman Kasianov
5
1
Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape
Drawing on new discussions from ARDD2025 in Copenhagen, the focus turns to how GLP-1s, IPF, and the gut microbiome are steering aging drug development
Nov 20, 2025
•
Andrii Buvailo, PhD
27
4
5
Weekly Tech+Bio Highlights #63: Quantum vs. AI Small Molecule Design
FDA’s pathway for custom gene editing, UK’s non-animal testing roadmap, OpenAI leads a biosecurity seed, 100x mRNA delivery & over $1B in fresh life…
Nov 18, 2025
•
Roman Kasianov
and
BiopharmaTrend
9
3
Protein Language Models: Builders & Pharma Deals
We unpack how PLMs work, notable builders, pharma deals, and current limitations
Nov 14, 2025
•
BiopharmaTrend
21
3
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
